HK1107088A1 - 3,6-substituted 5-arylamino-1h-pyidine-2-one derivatives and related compounds as poly(adp-ribose)polymerase (parp) inhibitors in the treatment of tissue damage or disease caused by necrosis or apoptosis - Google Patents

3,6-substituted 5-arylamino-1h-pyidine-2-one derivatives and related compounds as poly(adp-ribose)polymerase (parp) inhibitors in the treatment of tissue damage or disease caused by necrosis or apoptosis

Info

Publication number: HK1107088A1
Authority: HK; Hong Kong
Prior art keywords: parp; adp; ribose; polymerase; inhibitors
Prior art date: 2004-10-15

Application number

HK07112480.5A

Other languages

English (en)

Inventor

Stefan Peukert

Stefan Guessregen

Armin Hofmeister

Hermann Schreuder

Uwe Schwahn

Original Assignee

Sanofi Aventis Deutschland

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-10-15

Filing date

2007-11-15

Publication date

2008-03-28

2007-11-15 Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland

2008-03-28 Publication of HK1107088A1 publication Critical patent/HK1107088A1/xx

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Epidemiology (AREA)
Immunology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)

HK07112480.5A 2004-10-15 2007-11-15 3,6-substituted 5-arylamino-1h-pyidine-2-one derivatives and related compounds as poly(adp-ribose)polymerase (parp) inhibitors in the treatment of tissue damage or disease caused by necrosis or apoptosis HK1107088A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE102004050196A DE102004050196A1 (de)	2004-10-15	2004-10-15	Substituierte 2-Pyridon-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
PCT/EP2005/010697 WO2006042638A1 (de)	2004-10-15	2005-10-05	3,6-substituierte 5-arylamino-1h-pyidin-2-on derivative und verwandte verbindungen als poly(adp-ribose)polymerase (parp) inhibitoren zur behandlung von durch nekose oder apoptose verursachten gewebeschäden oder erkankungen

Publications (1)

Publication Number	Publication Date
HK1107088A1 true HK1107088A1 (en)	2008-03-28

Family

ID=35414525

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK07112480.5A HK1107088A1 (en)	2004-10-15	2007-11-15	3,6-substituted 5-arylamino-1h-pyidine-2-one derivatives and related compounds as poly(adp-ribose)polymerase (parp) inhibitors in the treatment of tissue damage or disease caused by necrosis or apoptosis

Country Status (17)

Country	Link
US (1)	US7863280B2 (xx)
EP (1)	EP1802578B1 (xx)
JP (1)	JP4875623B2 (xx)
KR (1)	KR20070063005A (xx)
CN (1)	CN101035761B (xx)
AT (1)	ATE393146T1 (xx)
AU (1)	AU2005297570C1 (xx)
BR (1)	BRPI0516516A (xx)
CA (1)	CA2583565A1 (xx)
DE (2)	DE102004050196A1 (xx)
DK (1)	DK1802578T3 (xx)
ES (1)	ES2304721T3 (xx)
HK (1)	HK1107088A1 (xx)
IL (1)	IL182093A (xx)
MX (1)	MX2007003360A (xx)
PT (1)	PT1802578E (xx)
WO (1)	WO2006042638A1 (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2003284237A1 (en) *	2002-10-16	2004-05-04	Transport Systems, Inc.	Monorail sortation system
US7961081B2 (en) *	2003-05-22	2011-06-14	John Tomlienovic	Anti-theft system and method
ZA200800907B (en)	2005-07-18	2010-04-28	Bipar Sciences Inc	Treatment of cancer
US8143447B2 (en)	2006-09-05	2012-03-27	Bipar Sciences, Inc.	Treatment of cancer
WO2008030891A2 (en) *	2006-09-05	2008-03-13	Bipar Sciences, Inc.	Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
WO2009012242A2 (en) *	2007-07-13	2009-01-22	Icagen, Inc.	Sodium channel inhibitors
EP2217227B1 (en)	2007-11-12	2013-08-21	BiPar Sciences, Inc.	Treatment of breast cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents
WO2011058367A2 (en)	2009-11-13	2011-05-19	Astrazeneca Ab	Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
US20130116284A1 (en)	2010-05-10	2013-05-09	Radikal Therapeutics Inc.	Lipoic acid and nitroxide derivatives and uses thereof
TW201512171A (zh)	2013-04-19	2015-04-01	Pfizer Ltd	化學化合物
PT3325623T (pt)	2015-07-23	2019-09-04	Inst Curie	Utilização de uma combinação de molécula dbait e de inibidores de parp para o tratamento do cancro
GB201519573D0 (en)	2015-11-05	2015-12-23	King S College London	Combination
WO2018162439A1 (en)	2017-03-08	2018-09-13	Onxeo	New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
US20200129476A1 (en)	2017-04-28	2020-04-30	Akribes Biomedical Gmbh	PARP Inhibitor in Combination with a Glucocorticoid and/or Ascorbic Acid and/or a Protein Growth Factor for the Treatment of Impaired Wound Healing
MA49566A (fr)	2017-07-11	2020-05-20	Vertex Pharma	Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques
JP2021515580A (ja)	2018-03-13	2021-06-24	オンクセオＯｎｘｅｏ	がんの治療における獲得耐性に対抗するｄｂａｉｔ分子
US20200247812A1 (en) *	2018-07-10	2020-08-06	Integral Biosciences Private Limited	Heterocyclic compounds and methods of use
WO2021064186A1 (en) *	2019-10-04	2021-04-08	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Novel pyridin-2(1h)one derivatives, their preparation and their use for the treatment of pain
WO2021146543A1 (en) *	2020-01-15	2021-07-22	The Trustees Of Princeton University	Inhibitors of glucose-6-phosphate dehydrogenase and uses thereof
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL70169A0 (en) *	1982-11-18	1984-02-29	Sterling Drug Inc	2(1h)-pyridinones,their preparation and pharmaceutical compositions containing them
GB9121651D0 (en) *	1991-10-11	1991-11-27	Smithkline Beecham Plc	Chemical compounds
JP2649610B2 (ja) *	1993-11-10	1997-09-03	日本たばこ産業株式会社	クロマン誘導体及びその医薬用途
ATE396978T1 (de) *	1999-10-07	2008-06-15	Amgen Inc	Triazin-kinase-hemmer
WO2003015785A1 (en) *	2001-08-15	2003-02-27	Icos Corporation	2h-phthalazin-1-ones and methods for use thereof
AUPS019702A0 (en) *	2002-01-29	2002-02-21	Fujisawa Pharmaceutical Co., Ltd.	Condensed heterocyclic compounds

2004
- 2004-10-15 DE DE102004050196A patent/DE102004050196A1/de not_active Withdrawn
2005
- 2005-10-05 WO PCT/EP2005/010697 patent/WO2006042638A1/de active IP Right Grant
- 2005-10-05 DE DE502005003866T patent/DE502005003866D1/de active Active
- 2005-10-05 BR BRPI0516516-4A patent/BRPI0516516A/pt not_active IP Right Cessation
- 2005-10-05 CN CN2005800338248A patent/CN101035761B/zh not_active Expired - Fee Related
- 2005-10-05 AT AT05788702T patent/ATE393146T1/de active
- 2005-10-05 AU AU2005297570A patent/AU2005297570C1/en not_active Ceased
- 2005-10-05 ES ES05788702T patent/ES2304721T3/es active Active
- 2005-10-05 PT PT05788702T patent/PT1802578E/pt unknown
- 2005-10-05 JP JP2007536043A patent/JP4875623B2/ja not_active Expired - Fee Related
- 2005-10-05 EP EP05788702A patent/EP1802578B1/de not_active Not-in-force
- 2005-10-05 KR KR1020077008550A patent/KR20070063005A/ko active IP Right Grant
- 2005-10-05 CA CA002583565A patent/CA2583565A1/en not_active Abandoned
- 2005-10-05 DK DK05788702T patent/DK1802578T3/da active
- 2005-10-05 MX MX2007003360A patent/MX2007003360A/es active IP Right Grant
2007
- 2007-03-21 IL IL182093A patent/IL182093A/en not_active IP Right Cessation
- 2007-04-11 US US11/733,833 patent/US7863280B2/en not_active Expired - Fee Related
- 2007-11-15 HK HK07112480.5A patent/HK1107088A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
KR20070063005A (ko)	2007-06-18
IL182093A (en)	2011-02-28
ES2304721T3 (es)	2008-10-16
WO2006042638A1 (de)	2006-04-27
US20070281948A1 (en)	2007-12-06
IL182093A0 (en)	2007-07-24
AU2005297570C1 (en)	2012-06-07
AU2005297570A1 (en)	2006-04-27
PT1802578E (pt)	2008-07-07
JP4875623B2 (ja)	2012-02-15
CN101035761B (zh)	2010-06-02
DE102004050196A1 (de)	2006-04-20
ATE393146T1 (de)	2008-05-15
CN101035761A (zh)	2007-09-12
BRPI0516516A (pt)	2008-09-16
MX2007003360A (es)	2007-05-23
EP1802578B1 (de)	2008-04-23
DE502005003866D1 (de)	2008-06-05
US7863280B2 (en)	2011-01-04
CA2583565A1 (en)	2006-04-27
DK1802578T3 (da)	2008-08-11
JP2008516902A (ja)	2008-05-22
AU2005297570B2 (en)	2011-06-16
EP1802578A1 (de)	2007-07-04

Legal Events

Date	Code	Title	Description
2015-04-30	PC	Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)	Effective date: 20141005

Publication	Publication Date	Title
IL182093A0 (en)	2007-07-24	3,6-substituted 5-arylamino-1h-pyridine-2-one derivatives and related compounds as poly(adp-ribose)polymerase (parp) inhibitors in the treatment of tissue damage or disease caused by necrosis or apoptosis
NO20063028L (no)	2006-06-28	6-substituerte 2-kinolinoner og 2-kinoksalinoner som poly(adp-ribose)-polymeraseinhibitorer
NO20076502L (no)	2008-02-19	Pyrrolopyridiner nyttige som inhibitorer av proteinkinase
NO20062892L (no)	2006-08-09	7-fenylalkyl-substituert 2-kinolinoner og 2-kinoksalinoner som poly(adp-ribose)-polymeraseinhibitorer
NO20063129L (no)	2006-07-05	Substituerte 6-cykloheksylalkylsubstituerte 2-kinolinoner og 2-kinoksalinoner som poly(ADP-ribose) polymeraseinhibitorer
NO20070555L (no)	2007-01-30	Kinazolinonderivater som parp-inhibitorer
NO20070557L (no)	2007-01-30	Ftalazinderivater som PARP-inhibitorer
NO20080675L (no)	2008-03-13	P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20076658L (no)	2008-04-04	Heteroarylbenzamidderivater for anvendelse som GLK aktivatorer ved behandling av diabetes
NO20062894L (no)	2006-08-09	6-alkenyl og 6-fenylalkylsubstituert 2-kinolinoner og 2-kinoksalinoner som poly(adp-ribose)polymeraseinhibitorer
NO20070526L (no)	2007-01-29	Kinazolindionderivater som parp-inhibitorer
WO2004087698A3 (en)	2004-12-09	Thiazoles useful as inhibitors of protein kinases
NO20082508L (no)	2008-07-31	Aminopyrimidiner anvendelige som kinaseinhibitorer
WO2007120647A3 (en)	2007-11-29	Compositions useful as inhibitors of voltage-gated sodium channels
MX2008005398A (es)	2008-09-24	Derivados de 4-(3-amino-pirazol)-pirimidina para uso como inhibidores de tirosina cinasa en el tratamiento de cancer.
NO20075626L (no)	2007-12-18	Heteroarylbenzamid-derivater for anvendelse som GLK-aktivatorer i behandling av diabetes
NO20053242L (no)	2005-07-01	4-substituerte benzimidazoler og deres anvendelse som inhibitorer av gastrisk sekresjon
NO20062726L (no)	2006-06-12	Nye pyridazin-3(2H)-on derivater
WO2007041130A3 (en)	2010-01-21	Deazapurines useful as inhibitors of janus kinases
TW200607805A (en)	2006-03-01	Novel pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
ATE540928T1 (de)	2012-01-15	Isochinolinverbindungen und ihre medizinische verwendung
MX2009002239A (es)	2009-04-27	Derivados de 5-(2-furil)-1,3-tiazol util como inhibidores de fosfatidilinositol 3-cinasa.
NO20084516L (no)	2009-01-13	Terfenylderivater for behandling av alzheimers sykdom
ATE553106T1 (de)	2012-04-15	Heteroarylpyrrolopyridinone als kinaseinhibitoren
IL186777A0 (en)	2008-02-09	(3,4-dihydro-quinazolin-2-yl) - (2-aryloxy-ethyl) - amines having an activity on the 5 - ht receptor